Clever Leaves Holdings Inc
OTC:CLVR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (0.3), the stock would be worth $0 (28% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | $0 |
0%
|
| 3-Year Average | 0.3 | $0 |
-28%
|
| Country Average | 14 413.7 | $18.71 |
+3 118 580%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$-6.1m
|
/ |
Jan 2024
$-13.2m
|
= |
|
|
$-6.1m
|
/ |
Dec 2024
$-5.1m
|
= |
|
|
$-6.1m
|
/ |
Dec 2025
$25.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CO |
|
Clever Leaves Holdings Inc
OTC:CLVR
|
1k USD | 0.5 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 16.2 | 29.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.5 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.2 | 17 |
Market Distribution
| Min | 2.7 |
| 30th Percentile | 8.7 |
| Median | 14 413.7 |
| 70th Percentile | 26 184.2 |
| Max | 326 289.4 |
Other Multiples
Clever Leaves Holdings Inc
Glance View
Clever Leaves Holdings Inc. is a leading player in the global cannabis industry, with a mission to provide high-quality, sustainable, and compliant cannabinoid products. Founded in 2018 and headquartered in New York, this vertically integrated company has established a robust operational presence in key markets, including Colombia, the United States, and Europe. Clever Leaves differentiates itself with a focus on international cultivation and distribution, leveraging Colombia's ideal climate for cannabis production, resulting in cost-effective and high-quality products. This strategic positioning allows the company to cater to a diverse customer base, from pharmaceutical companies to consumer brands, as it navigates the emerging global cannabinoid landscape. As an investor, you’ll find that Clever Leaves embodies the principles of responsible growth and innovation through its unwavering commitment to compliance and quality. With multiple certifications enabling it to trade in international markets, the company is well-prepared to capitalize on the evolving regulations surrounding cannabis. Their expansive research and development initiatives, along with solid supply chain management, aim to unlock new product opportunities, positioning Clever Leaves for potential long-term success in the burgeoning cannabinoid sector. As the global market continues to mature, Clever Leaves is poised to take advantage of expanding consumer demand for cannabis-derived products, making it an intriguing investment opportunity for those looking to enter this dynamic and rapidly growing industry.